Method of using Zven antibodies

Details Method of using Zven antibodies Method of using Zven antibodies

2006-10-13

2010-02-16

Bunner, Bridget E (Department: 1649)

Chemistry: analytical and immunological testing

Biospecific ligand binding assay

C435S007100, C530S350000, C530S387100, C530S388100, C530S389100, C530S391300

Reexamination Certificate

active

07662641

ABSTRACT:
The present invention provides novel uses two members of a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes. The invention also provides methods for using the antibodies to detect the presence of the protein with antibodies and methods for using the polynucleotides to detect the presence of Zven RNA.

REFERENCES:
patent: 5294630 (1994-03-01), Blake et al.
patent: 5891720 (1999-04-01), Moore et al.
patent: 6042821 (2000-03-01), DeMarsh et al.
patent: 6284725 (2001-09-01), Coolidge et al.
patent: 6485938 (2002-11-01), Sheppard et al.
patent: 6756479 (2004-06-01), Sheppard et al.
patent: 6828425 (2004-12-01), Sheppard et al.
patent: 7045299 (2006-05-01), Ohtaki et al.
patent: 7052674 (2006-05-01), Zhou et al.
patent: 7122349 (2006-10-01), Sheppard et al.
patent: 7179787 (2007-02-01), Sheppard et al.
patent: 7205110 (2007-04-01), Thompson et al.
patent: 7264801 (2007-09-01), Ferrara et al.
patent: 7291589 (2007-11-01), Thompson et al.
patent: 7531311 (2009-05-01), Thompson et al.
patent: 2002/0115610 (2002-08-01), Zhou et al.
patent: 2002/0187523 (2002-12-01), Tang et al.
patent: 2002/0188330 (2002-12-01), Gielen et al.
patent: 2002/0192634 (2002-12-01), Ferrara et al.
patent: 2005/0037464 (2005-02-01), Zhou et al.
patent: 2007/0042417 (2007-02-01), Sheppard et al.
patent: 2007/0042960 (2007-02-01), Sheppard et al.
patent: 2007/0048258 (2007-03-01), Thompson et al.
patent: 2007/0048778 (2007-03-01), Thompson et al.
patent: 2007/0048840 (2007-03-01), Thompson et al.
patent: 2007/0049526 (2007-03-01), Thompson et al.
patent: 2007/0053907 (2007-03-01), Thompson et al.
patent: 2007/0053908 (2007-03-01), Thompson et al.
patent: 2007/0065403 (2007-03-01), Thompson et al.
patent: 2007/0065404 (2007-03-01), Thompson et al.
patent: 2007/0065405 (2007-03-01), Thompson et al.
patent: 2007/0078259 (2007-04-01), Thompson et al.
patent: 2007/0087414 (2007-04-01), Thompson et al.
patent: 2007/0092912 (2007-04-01), Thompson et al.
patent: 2007/0172889 (2007-07-01), Sheppard et al.
patent: 2008/0219985 (2008-09-01), Thompson et al.
patent: 1357129 (2003-10-01), None
patent: 1506971 (2005-02-01), None
patent: 1589033 (2005-10-01), None
patent: 1688434 (2006-08-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/63088 (1999-12-01), None
patent: WO 01/36465 (2001-05-01), None
patent: WO 01/48015 (2001-07-01), None
patent: WO 02/36625 (2002-05-01), None
patent: WO 02/062944 (2002-08-01), None
patent: WO 03/40326 (2003-05-01), None
patent: WO 04/31367 (2004-04-01), None
patent: WO 04/040000 (2004-05-01), None
patent: WO 04/65419 (2004-08-01), None
patent: WO 04/81229 (2004-09-01), None
patent: WO 05/37870 (2005-04-01), None
Mollay et al. “Bv8, a small protein from frog skin and its homologue from snake venom induc hyperalgensia in rats.” Euro. J. Pharmacol. 374:189-196 (1999).
Panés, J. “Inflammatory bowel disease: pathogenesis and targets for therapeutic interventions.” Acta. Physioi. Scand, 173:159-165 (2001).
Bassil et al., “Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon”, European Journal of Pharmacology 524:138-144, 2005.
Boisbouvier et al. “A Structural Homologue of Colipase in Black Mamba Venom Revealed by NMR Floating Disulphide Bridge Analysis,” J. Mol. Biol. 283: 205-219, 1998.
EMBL Accession No. AF182066, Dec. 14, 1999.
EMBL Accession No. AF182069, Oct. 2, 2000.
EMBL Accession No. AF333024, May 5, 2001.
EMBL Accession No. AF333025, May 5, 2001.
Fedi et al., “Isolation and Biochemical Characterization of the Human Dkk-1 Homologue, a Novel Inhibitor of Mammalian Wnt Signaling,” J.Biol. Chem. 274(27): 19465-19472, 1999.
Harlow et al., “Antibodies A Laboratory Manual,” Cold Spring Harbor Laboratory, pp. 76, 361, 476, 555 and 626, 1988.
Hsieh et al., “A new secreted protein that binds to Wnt proteins and inhibits their activities,” Nature 398: 431-436, 1999.
Jilek et al., “MurineBv8Gene Maps Near a Synteny Breakpoint of Mouse Chromosome 6 and Human 3p21,” Gene 256: 189-195, 2000.
Joubert et al., “The Amino Acid Sequence of Protein a from dendroaspis polylepis polylepis (Black mamba) Venom,” Hoppe Seylers Z Physiol Chem. 361(12): 1787-94, 1980.
Li et al., “Identification of Two Prokineticin cDNAs: Recombinant Proteins Potently Contract Gastrointestinal Smooth Muscle,” Molec. Pharmacol. 59(4): 692-698, 2001.
Morrison et al., “Genetically Engineered Antibody Molecules,” Advances in Immunology 44: 65.92, 1989.
Schweitz et al., “MIT1, a Black Mamba Toxin With a New and Highly Potent Activity on Intestinal Contraction,” FEBS Lett. 461: 183-188, 1999.
Wechselberger et al., “The Mammalian Homologues of Frog Bv8 are Mainly Expressed in Spermatocytes,” FEBS Lett. 462: 177-181, 1999.
WPI Accession No. 2004-593431, 2004.
WPI Accession No. 2005-322854, 2005.
International Search Report dated Aug. 3, 2001 for Application No. PCT/US00/31278, filed Nov. 14, 2000.
Baumgart et al., “Inflammatory Bowel Disease: Cause and Immunobiology,” Lancet 369(9573): 1627-1640, 2007.
Casset et al., “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design,” Biochem Biophys Res Commun. 307: 198-205, 2003.
Colman et al., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Res Immuno. 145(1): 33 36, Jan. 1994.
Database UniPrto [Online] “RecName: Full=Prokineticin-2; Short=PK2; Altname: Full=Protein Bv8 homolog; Flags: Precursor.” EBI accession no. UNIPROT:Q9HC23; Database Accession no. Q9HC23 (Sep. 26, 2001).
Lin et al. “Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor.” Journal of Biological Chemistry. 277(22):19276-19280 (2002).
MacCallum et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” J Mol Biol 262: 732-745, 1996.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” inThe Protein Folding Problem and Tertiary Structure Predictionby Merz et al., Eds. Pp. 491-495, 1994.
Paul, (Ed) “Structure and Function of Immunoglobulins”, Fundamental Immunology, 3rd Edition, Raven Press, NY, 1993, pp. 292-295, Chapter 9.
Rudikoff et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity,” PNAS USA 79: 1979-1983, Mar. 1982.
Wells, James A., “Additivity of Mutational Effects in Proteins,” Biochemistry 29(37): 8509-8517, 1990.
Xavier et al., “Unravelling the Pathogenesis of Inflammatory Bowel Disease,” Nature 448: 427-434, 2007.
European Search Report for European Application No. 03773168.4, dated Jun. 10, 2009.
Supplementary European Search Report for European Application No. 03786525.0, dated Jun. 15, 2009.

Affiliated with

Also associated with

Rating

Method of using Zven antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of using Zven antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using Zven antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4203609